We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+5.62%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.2B
AUM Growth
+$36.4M
Cap. Flow
+$49.6M
Cap. Flow %
2.25%
Top 10 Hldgs %
26.49%
Holding
159
New
12
Increased
46
Reduced
21
Closed
14

Top Buys

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$23.1M
2
SYK icon
Stryker
SYK
+$19.3M
3
HOLX
Hologic
HOLX
+$13.4M
4
ZBH icon
Zimmer Biomet
ZBH
+$11.4M
5
MOH icon
Molina Healthcare
MOH
+$10.4M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$27.5M
2
DHR icon
Danaher
DHR
+$19.3M
3
MDT icon
Medtronic
MDT
+$19.2M
4
BCR
CR Bard Inc.
BCR
+$18.4M
5
WCG
Wellcare Health Plans, Inc.
WCG
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.16%
2 Financials 2.8%
3 Consumer Discretionary 0.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
26
Vertex Pharmaceuticals
VRTX
$123B
$25.7M 1.16%
171,250
+19,750
+13% +$2.92M
EXAS
27
DELISTED
Exact Sciences
EXAS
$22.9M 1.04%
434,900
-2,500
-0.6% -$133K
TFX icon
28
Teleflex
TFX
$6.15B
$22.8M 1.04%
+91,750
New +$23.1M
IRTC icon
29
iRhythm Holdings
IRTC
$4.21B
$22.8M 1.03%
406,000
+20,000
+5% +$1.05M
GILD icon
30
Gilead Sciences
GILD
$162B
$22.5M 1.02%
313,400
– –
MRSN
31
DELISTED
Mersana Therapeutics
MRSN
$21.8M 0.99%
53,072
-128
-0.2% -$55.8K
EW icon
32
Edwards Lifesciences
EW
$51.5B
$21.4M 0.97%
570,003
– –
TMO icon
33
Thermo Fisher Scientific
TMO
$214B
$20.9M 0.95%
110,000
– –
ASMB icon
34
Assembly Biosciences
ASMB
$524M
$20.4M 0.92%
37,500
+5,000
+15% +$2.26M
SYK icon
35
Stryker
SYK
$129B
$19.6M 0.89%
+126,500
New +$19.3M
AVXS
36
DELISTED
AveXis, Inc. Common Stock
AVXS
$19.4M 0.88%
175,000
– –
INSM icon
37
Insmed
INSM
$28.7B
$19.1M 0.87%
613,500
-36,500
-6% -$1.08M
MDCO
38
DELISTED
Medicines Co
MDCO
$18.9M 0.86%
690,000
– –
WTW icon
39
Willis Towers Watson
WTW
$31.6B
$18.5M 0.84%
123,000
+8,000
+7% +$1.26M
TBPH icon
40
Theravance Biopharma
TBPH
$877M
$18.2M 0.83%
652,600
+8,200
+1% +$243K
LKFT
41
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$17.3M 0.79%
185,000
-29,000
-14% -$2.74M
INCY icon
42
Incyte
INCY
$24B
$17.3M 0.78%
182,500
+9,500
+5% +$993K
BIIB icon
43
Biogen
BIIB
$30.5B
$16.9M 0.77%
53,000
– –
JAZZ icon
44
Jazz Pharmaceuticals
JAZZ
$16.7B
$16.7M 0.76%
123,700
– –
EPZM
45
DELISTED
Epizyme, Inc
EPZM
$16.6M 0.75%
1,325,000
-25,000
-2% -$363K
ALNY icon
46
Alnylam Pharmaceuticals
ALNY
$28.9B
$16.5M 0.75%
130,000
+25,000
+24% +$3.14M
BOLD
47
DELISTED
Audentes Therapeutics, Inc
BOLD
$16.4M 0.74%
525,000
– –
AMRN
48
Amarin Corp
AMRN
$301M
$15.8M 0.72%
197,500
-2,500
-1% -$172K
PTLA
49
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$15.8M 0.72%
323,800
– –
CLVS
50
DELISTED
Clovis Oncology, Inc.
CLVS
$15.7M 0.71%
231,500
– –
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return

Rock Springs Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Rock Springs Capital Management held 159 positions worth $2.2B, up 1.7% from $2.17B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rock Springs Capital Management's Q4 2017 filing shows 12 new, 46 increased, 21 reduced and 14 closed positions. Its largest new stake was Teleflex: 91,750 shares worth $22.8M. The largest sale was Aetna Inc, an estimated $27.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 80% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q4 2017 buy was Teleflex: 91,750 shares worth $22.8M.
  • Rock Springs Capital Management added most to Zimmer Biomet in Q4 2017, an estimated $11.4M increase.
  • Rock Springs Capital Management's biggest Q4 2017 reduction was Aetna Inc, cutting an estimated $27.5M.
  • Rock Springs Capital Management fully exited Danaher in Q4 2017, selling an estimated $19.3M.
  • Rock Springs Capital Management's ten largest holdings make up 26% of its $2.2B portfolio in Q4 2017.
  • Rock Springs Capital Management opened 12 new positions and closed 14 in Q4 2017.
  • Rock Springs Capital Management's portfolio value rose 1.7% quarter-over-quarter to $2.2B.

Based on Rock Springs Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.